Biomarkers of chronic inflammation and cognitive decline: A prospective observational study

Biomarkers of chronic inflammation and cognitive decline: A prospective observational study

Abstract We sought to determine whether the biomarkers of chronic inflammation predict cognitive decline in a prospective observational study. We measured baseline serum soluble urokinase plasminogen activator receptor (suPAR) and high sensitivity C‐reactive protein (hs‐CRP) levels in 282 participan...

Full description

Bibliographic Details
Main Authors:	Bhavna A. Guduguntla, Alexi Vasbinder, Elizabeth Anderson, Tariq U. Azam, Pennelope Blakely, Noah J. Webster, Richard Gonzalez, Toni Atonucci, Judith L. Heidebrink, Bruno Giordani, Laura Zahodne, Benjamin M. Hampstead, Kristine J. Ajrouch, Salim S. Hayek
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:	Alzheimer's disease cognition dementia hs‐CRP suPAR
Online Access:	https://doi.org/10.1002/dad2.12568

Similar Items

Immune Activation Mediates the Association of Advanced Hepatic Fibrosis With Adverse Outcomes in Patients With Coronary Artery Disease
by: Vardhmaan Jain, et al.
Published: (2023-12-01)

Alterations in inflammatory markers after a 12-week exercise program in individuals with schizophrenia—a randomized controlled trial
by: Therese Torgersen Bigseth, et al.
Published: (2023-05-01)

Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants
by: Tudorita Gabriela Paranga, et al.
Published: (2023-06-01)

Pre-hospital suPAR, lactate and CRP measurements for decision-making: a prospective, observational study of patients presenting non-specific complaints
by: Milla Jousi, et al.
Published: (2021-10-01)

Prospective use of soluble urokinase plasminogen activator receptor to screen TB co-infected with HIV patient among TB patient
by: Tri Yudani Mardining Raras, et al.
Published: (2017-10-01)

suPAR and WT1 modify the adhesion of podocytes and are related to proteinuria in class IV lupus nephritis
by: Juan-José Bollain-y-Goytia, et al.
Published: (2023-12-01)

The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
by: Kristian Blomberg, et al.
Published: (2021-10-01)

Kinetics of SuPAR hemoadsorption in critical COVID-19 patients on renal replacement therapy
by: Vaidas Vicka, et al.
Published: (2022-11-01)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
by: Mohamed Abd‑Ellatif El‑Patal, et al.
Published: (2022-10-01)

Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure
by: Yunyun Wang, et al.
Published: (2021-11-01)

suPAR, a Circulating Kidney Disease Factor
by: Changli Wei, et al.
Published: (2021-10-01)

Concentrations of urinary neopterin, but not suPAR, positively correlate with age in rhesus macaques
by: Eve B. Cooper, et al.
Published: (2022-10-01)

suPAR as a marker of infection in acute kidney injury – a prospective observational study
by: Anna Hall, et al.
Published: (2018-08-01)

Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS
by: Sven H. Loosen, et al.
Published: (2024-05-01)

The predictive value of modified soluble urokinase plasminogen activator receptor (suPAR) with National Early Warning Score (NEWS) for mortality in emergency elderly patients in Japan: a prospective pilot study
by: Toshiya Mitsunaga, et al.
Published: (2023-01-01)

Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery
by: Athanasios Chalkias, et al.
Published: (2022-06-01)

Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis
by: Wenjuan Wu, et al.
Published: (2018-05-01)

suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department
by: Seppälä Santeri, et al.
Published: (2021-11-01)

Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction
by: Nils A. Sörensen, et al.
Published: (2019-03-01)

The Perspective of Vitamin D on suPAR-Related AKI in COVID-19
by: Tzu-Hsien Liao, et al.
Published: (2022-09-01)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
by: Anurag Mehta, et al.
Published: (2020-03-01)

Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection
by: Sebastian M. Klim, et al.
Published: (2024-02-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
by: Mariangela Manfredi, et al.
Published: (2023-04-01)

Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
by: Alice G. Vassiliou, et al.
Published: (2022-05-01)

Reassessing the Reassessment of suPAR in glomerular disease
by: Björn eMeijers, et al.
Published: (2015-01-01)

Analysis of some sepsis markers: C-reactive protein, Procalcitonin, Osteopontin and suPAR
by: Ilaria Crespi, et al.
Published: (2010-09-01)

Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis
by: Jing-jing Zhao, et al.
Published: (2018-05-01)

Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab
by: Nada Alachkar, et al.
Published: (2018-12-01)

Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis
by: Hidi A. A. Abdellatif, et al.
Published: (2023-04-01)

Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
by: Filomena Napolitano, et al.
Published: (2021-10-01)

Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study
by: Qiongzhen Luo, et al.
Published: (2018-01-01)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
by: Rahul Gupta
Published: (2022-04-01)

Work ability assessment among acutely admitted patients using biomarkers
by: Ove Andersen, et al.
Published: (2017-12-01)

Plasminogen System in the Pathophysiology of Sepsis: Upcoming Biomarkers
by: Filomena Napolitano, et al.
Published: (2023-08-01)

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trialResearch in context
by: Karolina Akinosoglou, et al.
Published: (2023-02-01)

Variability in CKD Biomarker Studies: Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Kidney Disease Progression in the Chronic Kidney Disease in Children (CKiD) StudyPlain-Language Summary
by: Alison G. Abraham, et al.
Published: (2021-09-01)

Ability of combined soluble urokinase plasminogen activator receptor to predict preventable emergency attendance in older patients in Japan: a prospective pilot study
by: Toshiya Mitsunaga, et al.
Published: (2022-11-01)

The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults
by: Niklas Fabio Wohlwend, et al.
Published: (2023-09-01)

Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke
by: Dorota Różański, et al.
Published: (2021-12-01)

Studying the estimation levels of inflammatory markers and NF-?B in MDR and DS-TB patients
by: Yassmeen A. Hussain, et al.
Published: (2023-04-01)